B of A Securities Reinstates Neutral on Gilead Sciences, Announces $85 Price Target
B of A Securities analyst Geoff Meacham reinstates Gilead Sciences (NASDAQ:GILD) with a Neutral and announces $85 price target.
Cowen & Co. Initiates Coverage On Okta with Market Perform Rating, Announces Price Target of $70
Cowen & Co. analyst Shaul Eyal initiates coverage on Okta (NASDAQ:OKTA) with a Market Perform rating and announces Price Target of $70.
JP Morgan Initiates Coverage On MSCI with Overweight Rating, Announces Price Target of $580
JP Morgan analyst Alexander Hess initiates coverage on MSCI (NYSE:MSCI) with a Overweight rating and announces Price Target of $580.
B. Riley Securities Initiates Coverage On Saratoga Investment with Buy Rating, Announces Price Target of $27.5
B. Riley Securities analyst Bryce Rowe initiates coverage on Saratoga Investment (NYSE:SAR) with a Buy rating and announces Price Target of $27.5.
Citigroup Initiates Coverage On Beam Therapeutics with Buy Rating, Announces Price Target of $62
Citigroup analyst Samantha Semenkow initiates coverage on Beam Therapeutics (NASDAQ:BEAM) with a Buy rating and announces Price Target of $62.
Citigroup Initiates Coverage On VeriSign with Buy Rating, Announces Price Target of $243
Citigroup analyst Ygal Arounian initiates coverage on VeriSign (NASDAQ:VRSN) with a Buy rating and announces Price Target of $243.
Piper Sandler Assumes American Express at Neutral, Announces Price Target of $159
Piper Sandler analyst Kevin Barker assumes American Express (NYSE:AXP) with a Neutral rating and announces Price Target of $159.
Piper Sandler Assumes PayPal Holdings at Neutral, Announces Price Target of $85
Piper Sandler analyst Kevin Barker assumes PayPal Holdings (NASDAQ:PYPL) with a Neutral rating and announces Price Target of $85.
EF Hutton Initiates Coverage On Coeptis Therapeutics with Buy Rating, Announces Price Target of $6
EF Hutton analyst Michael King initiates coverage on Coeptis Therapeutics (NASDAQ:COEP) with a Buy rating and announces Price Target of $6.
SVB Leerink Initiates Coverage On ARS Pharmaceuticals with Outperform Rating, Announces Price Target of $14
SVB Leerink analyst Roanna Ruiz initiates coverage on ARS Pharmaceuticals (NASDAQ:SPRY) with a Outperform rating and announces Price Target of $14.